載入中
NASDAQBasic MaterialsOther Precious Metals
最新資料
US$5.13
−US$0.75 · -12.76%
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
前收盤價
US$5.13
−US$0.75 · -12.76%
盤中時間採用ET。市場資料可能有所延遲。
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
日內區間
目前US$5.13
52週區間
目前US$5.13
盤中時間採用ET。市場資料可能有所延遲。
Greenland Mines Ltd operates across two segments: natural resources and cell and gene therapy. Its resources arm is focused on exploring for palladium, gold, and platinum, centered on the exploration and development of the Skaergaard project in Southeast Greenland. On the therapeutics side, the company is developing KLTO-202, a gene therapy targeting the treatment and prevention of amyotrophic lateral sclerosis (ALS), and KLTO-101, aimed at treating or preventing Alzheimer's disease, alongside therapies for Parkinson's and other age-related conditions. Previously known as Klotho Neurosciences, Inc., the company adopted its current name in March 2026. It is headquartered in Charlotte, North Carolina.
日內區間
目前US$5.13
52週區間
目前US$5.13
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 63.42萬 USD | — | — | — | — |
| 銷售、一般及管理費用 | 651.21萬 USD | 554.02萬 USD | 63.13萬 USD | 53.4萬 USD | 110.91萬 USD |
| 營業費用 | 714.63萬 USD | 554.02萬 USD | 63.13萬 USD | 65.7萬 USD | 110.91萬 USD |
| 利息收入 | — | — | — | 128.05萬 USD | — |
| 利息支出 | 231.4萬 USD | 35.66萬 USD | 7.62萬 USD | — | — |
| 折舊和攤銷 | — | — | — | — | 110.91萬 USD |
| 營業利益 | −714.63萬 USD | −554.02萬 USD | −63.13萬 USD | −65.7萬 USD | −110.91萬 USD |
| 淨利 | −1055.17萬 USD | −615.04萬 USD | −70.75萬 USD | 123.34萬 USD | −110.9萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
